Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Regeneron predicts 300,000 COVID-19 cocktail doses ready by January, and 'substantially more' in 2021
McConnell wants to help hospitals in lame-duck COVID-19 package
AstraZeneca targets severe COVID-19 patients for antibody therapy despite Regeneron, Lilly setbacks
Bristol Myers Squibb, fueled by COVID-19 and social justice movement, ramps up diversity efforts in clinical trials
Humanigen links drug to improvements in severe COVID-19 patients
Healthcare employment up 58K in October but recovery remains sluggish
Biopharma roundup: Novartis' Ilaris sputters in COVID trial; AstraZeneca to file ex-U.S. shot data for FDA nod
Change Healthcare see potential growth as IT budgets increase during COVID-19

Featured Story

Regeneron predicts 300,000 COVID-19 cocktail doses ready by January, and 'substantially more' in 2021

By Eric Sagonowsky

Like many of its peers, Regeneron responded swiftly to the COVID-19 pandemic and moved treatment candidates quickly through testing. Now that its antibody cocktail has shown promise—and as the raging pandemic hits new heights in the U.S.—the company is amping up its efforts to manufacture hundreds of thousands of doses.

McConnell wants to help hospitals in lame-duck COVID-19 package

By Robert King

Senate Majority Leader Mitch McConnell expressed a desire to help hospitals in the next COVID-19 relief package Congress is expected to debate during the lame-duck session next week, but divisions with Democrats remain.

AstraZeneca targets severe COVID-19 patients for antibody therapy despite Regeneron, Lilly setbacks

By Nick Paul Taylor

AstraZeneca has talked up the prospects of its anti-SARS-CoV-2 antibody working in severe COVID-19 patients despite rival assets from Eli Lilly and Regeneron failing in that population. Mene Pangalos, an AstraZeneca EVP, made the comments while sharing news the antibody is set to start a prophylaxis study next week.

Bristol Myers Squibb, fueled by COVID-19 and social justice movement, ramps up diversity efforts in clinical trials

By Amirah Al Idrus

Bristol Myers Squibb was already working on a plan to boost diversity in clinical trials, but the events of 2020—namely a pandemic that disproportionately affects minorities and a social justice movement reignited by the murder of George Floyd—ramped up its efforts.

Humanigen links drug to improvements in severe COVID-19 patients

By Nick Paul Taylor

Humanigen has estimated its anti-GM-CSF antibody caused 37% more recoveries than standard of care in hospitalized COVID-19 patients. The data remain blinded, but Humanigen calculated the effect of the drug based on the changes to enrollment requested by the data safety monitoring board.

Healthcare employment up 58K in October but recovery remains sluggish

By Robert King

The healthcare industry added 58,000 new jobs last month, but the recovery from the COVID-19 financial crisis is slowing in the sector.

Biopharma roundup: Novartis' Ilaris sputters in COVID trial; AstraZeneca to file ex-U.S. shot data for FDA nod

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

Novartis' arthritis drug Ilaris stumbled in a phase 3 COVID trial. AstraZeneca may file ex-U.S. vaccine data to the FDA. The Recovery Trial is testing aspirin in hospitalized coronavirus patients. Regeneron is optimistic about the FDA's decision on its antibody cocktail. And Amgen HQ staffers will work remotely through June.

Change Healthcare see potential growth as IT budgets increase during COVID-19

By Heather Landi

A rebound in healthcare utilization and new technology bookings helped Change Healthcare to achieve better-than-expected results in the third quarter of 2020. Find out how the company performed in its most recent fiscal quarter and why executives think the company is positioned well as healthcare evolves during the pandemic.

COVID-19 Tracker